Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 17/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.55 |
| ▸ | USP2 | O75604 | 10/20 | 0.55 |
| ▸ | CASP1 | P29466 | 7/20 | 0.55 |
| ▸ | CASP7 | P55210 | 6/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928698 | 0.88 | CYP1A2 (0.65) | CYP1A2ALDH1A1USP2CASP1CASP7 | |
| SCHEMBL927948 | 0.87 | CYP1A2 (0.64) | CYP1A2ALDH1A1USP2CASP1CASP7 | |
| SCHEMBL15457529 | 0.84 | CYP1A2 (0.50) | CYP1A2ALDH1A1USP2CASP1CASP7 | |
| SCHEMBL928927 | 0.84 | CYP1A2 (0.50) | CYP1A2ALDH1A1USP2CASP1CASP7 | |
| SCHEMBL983445 | 0.83 | ALDH1A1 (0.56) | CYP1A2ALDH1A1USP2CASP1CASP7 | |
| SCHEMBL3442299 | 0.81 | CYP1A2 (0.54) | CYP1A2ALDH1A1USP2CASP1CASP7 | |
| SCHEMBL14635648 | 0.78 | CYP1A2 (0.66) | CYP1A2ALDH1A1USP2CASP1CASP7 | |
| SCHEMBL16083674 | 0.75 | RPS6KA5 (0.52) | RPS6KA5CYP11B1CYP11B2 | |
| SCHEMBL927120 | 0.75 | CYP1A2 (0.60) | CYP1A2ALDH1A1USP2CASP1CASP7 | |
| SCHEMBL927609 | 0.72 | CYP1A2 (0.64) | CYP1A2ALDH1A1USP2CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642617-B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-02-04 | — | — | US | claimed |
| US-8609689-B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2013-12-17 | — | — | US | claimed |
| US-20130023537-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | claimed |
| US-20120122876-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | BOTTON GERARD (FR) | 2012-05-17 | — | — | US | claimed |
| US-20110009417-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | claimed |
| EP-2247292-B1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2017-04-12 | — | — | EP | disclosed |
| EP-2247292-B1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-8642617-B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642617-B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642617-B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8609689-B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20130023537-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8178556-B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-15 | — | — | US | disclosed |
| US-8178556-B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20110009417-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009417-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009417-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2247292-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009109341-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109341-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023537-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | IAPP, GLP1R, PDXK | CYP1A2 363/4885ALDH1A1 3137/4885USP2 4373/4885 |
| US-20120122876-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | IAPP, GLP1R, PDXK | CYP1A2 363/4885ALDH1A1 3137/4885USP2 4373/4885 |
| US-20110009417-A1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | IAPP, GLP1R, PDXK | CYP1A2 395/4885ALDH1A1 3488/4885USP2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.